Denali Therapeutics Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2017 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Denali Therapeutics Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2017 to Q2 2024.
  • Denali Therapeutics Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$99M, a 154% decline year-over-year.
  • Denali Therapeutics Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$420M, a 227% decline year-over-year.
  • Denali Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$145M, a 55.5% increase from 2022.
  • Denali Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$326M, a 12.2% decline from 2021.
  • Denali Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$291M, a 508% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$420M -$99M -$282M -154% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-01
Q1 2024 -$137M -$102M +$7.98M +7.27% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 -$145M -$119M -$20.8M -21.1% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 -$124M -$99.4M +$3.95M +3.82% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-07
Q2 2023 -$128M $183M +$242M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 -$371M -$110M -$44.6M -68.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 -$326M -$98.7M -$23.4M -31.1% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 -$303M -$103M -$18.7M -22.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 -$284M -$58.8M +$1.9M +3.13% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$286M -$65.2M +$4.82M +6.88% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 -$291M -$75.3M -$320M -131% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 $29.6M -$84.6M -$26.4M -45.3% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $55.9M -$60.7M -$1.93M -3.29% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $57.9M -$70M -$13.3M -23.4% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $71.1M $245M +$299M Oct 1, 2020 Dec 31, 2020 10-K 2023-02-27
Q3 2020 -$228M -$58.2M -$12M -25.9% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$216M -$58.8M -$421K -0.72% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-04
Q1 2020 -$215M -$56.8M -$17.8M -45.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 -$198M -$54M -$132M -170% Oct 1, 2019 Dec 31, 2019 10-K 2020-02-27
Q3 2019 -$66.1M -$46.3M -$10.9M -30.8% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$55.2M -$58.3M -$3.61M -6.6% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-07
Q1 2019 -$51.6M -$39M -$15.3M -64.7% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$36.2M $77.5M +$100M Oct 1, 2018 Dec 31, 2018 10-K 2020-02-27
Q3 2018 -$137M -$35.4M -$13.5M -61.9% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-27
Q2 2018 -$123M -$54.7M -$32.6M -147% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-27
Q1 2018 -$90.5M -$23.7M -$2.36M -11.1% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-27
Q4 2017 -$88.2M -$22.9M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-12
Q3 2017 -$21.8M Jul 1, 2017 Sep 30, 2017 10-K 2019-03-12
Q2 2017 -$22.1M Apr 1, 2017 Jun 30, 2017 10-K 2019-03-12
Q1 2017 -$21.3M Jan 1, 2017 Mar 31, 2017 10-K 2019-03-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.